Filing Flows

Filing Flows › Health Care › BullFrog AI Holdings (BFRG)

BullFrog AI Holdings (BFRG) earnings and revenue breakdown

Latest: Q2 2026 · 10-Q filed Aug 14, 2026 · BullFrog AI Holdings (BFRG) Q2 2026 earnings results →

Q2 2026 Revenue up 548% year over year to $215K · 637¢ of every $1 of revenue lost · operating margin -658.8%

BullFrog AI Holdings made $215K in Q2 2026 (+548% Y/Y). Operating margin -658.8%, net loss $1.4M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 14, 2026.

Revenue$215K
Year over year+548%
Operating margin-658.8%
Net earnings−$1.4M
Operating cash flow−$1.5M

Drawing the Sankey…

Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF

What changed this quarter

Revenue was $215K in Q2 2026, up 548% year over year.

Gross margin was 49.6%, up 30.0 points from Q2 2025. Operating costs exceeded revenue by $1.4M, an operating margin of -658.8%. Operating expenses grew 3% against revenue growth of 548%. The fastest-growing cost line was General & admin (+19%). The quarter ended with a net loss of $1.4M.

Operating cash flow was −$1.5M. Non-cash charges added back $0K of depreciation and $110K of share-based compensation. Working capital and other items used $252K.

Quarterly history

BullFrog AI Holdings revenue by quarterBullFrog AI Holdings revenue by quarter$33KQ2 2025$83KQ3 2025$215KQ2 2026
BullFrog AI Holdings net earnings by quarterBullFrog AI Holdings net earnings by quarter−$1.4MQ2 2025−$1.6MQ3 2025−$1.4MQ2 2026
QuarterFormFiledRevenueY/YOp. marginNet earningsOp. cash flow
Q2 202610-QAug 14, 2026$215K+548%-658.8%−$1.4M−$1.5M
Q3 202510-QNov 14, 2025$83K—n/m−$1.6M−$1.1M
Q2 202510-QAug 13, 2025$33K—n/m−$1.4M−$1.4M

Charts

BullFrog AI Holdings: where the cash came from (+) and went (−), TTM to Q2 2026BullFrog AI Holdings: where the cash came from (+) and went (−), TTM to Q2 2026Shares issued$10.1MOperating cash flow−$5.5MCash drawn (+) / kept (−)−$4.4MOther financing−$93KNet borrowing (+) / repaid (−)−$20K
From the cash-flow statement as filed (SEC XBRL). Cash is fungible: the bars do not say which dollar paid for what.
BullFrog AI Holdings: profit against cash, quarter by quarterBullFrog AI Holdings: profit against cash, quarter by quarterNet incomeOperating cash flow−$1.8M−$1.2MQ3 2024−$1.7M−$1.3MQ4 2024−$2.0M−$1.8MQ1 2025−$1.4M−$1.4MQ2 2025−$1.6M−$1.1MQ3 2025−$1.5M−$1.2MQ4 2025−$1.6M−$1.7MQ1 2026−$1.4M−$1.5MQ2 2026
Latest (Q2 2026): Net income −$1.4M, Operating cash flow −$1.5M.
BullFrog AI Holdings: diluted shares by fiscal yearBullFrog AI Holdings: diluted shares by fiscal year4MFY20226MFY20238MFY202410MFY2025
+157.8% since FY2022: more shares outstanding (issuance, stock pay).
BullFrog AI Holdings in its industry: growth against margin (225 companies, SIC 2834)BullFrog AI Holdings in its industry: growth against margin (225 companies, SIC 2834)revenue growth, year over year →↑ operating marginmedian +11%median -50%JNJLLYMRKABBVPFEBMYABTREGNTEVAVTRSVRTXBHCZTSONCOGNALNYELANJAZZBMRNPRGOAMRXUTHRRPRXNRIXINSMKeenova Therapeutics plcALKSMDGLPAHCSRPTPTCTINDVBBIOACADCORTPBHANIPKNSAPTGXHRMYIONSAXSMTGTXSUPNTVTXCOLLVREOFAMPHMIRMPCRXRARELQDAARQTIRWDARDXNATRXNCREBSZLABXERSINVACRMDMNKDRYTMURGNPHATAUPHSNDXRIGLLGNDEOLSARWRPGENHROWVNDAOPKSDGRGERNETONAGIOPBYITNGXCYRXCYTKMRVIORGONUVBLFVNSIGAKROSAMRNZVRASPRYHRTXAKBABCYCKPTIGYREMGNXELTPSEPNVRDNLFCRCrinetics Pharmaceuticals, Inc.VSTMKURATBPHLABADCTNAMSFBIOXLODERMARCTRMTIAYTUFHTXENTATNXPOCULASMBWVEAPMDBFRIABEOSTOKLXRXCAPRIDYANKTRZOMDFINBPJANXSBFMGOSSETSTRCUSCPIXLIFDCUEAQSTPRAXWHWKVERUEMMAGENBVRCACELUQUREZYMEEQABCLIMNMKYNBAKTSRNACVSICNTBTRAWISCOEVFMTVRDLPCNCAMPAtaiBeckley Inc.CTMXALMSPMHSACRSVTGNROIVKRROJAGXENSCKRSAABUSPRPHSTTKCPHITRDATXMDGOVXNWBOBIOEUPBIRDOVIDSPRBXBIOPRTAMCRBARVNMNOVSLNIGCBIOALGVNDNTHCPMDSPRORFLCOYASCYXSXTPBTAIQHCWBSERYARWRNACRGBPAVTXCLNNNTHIHINDAAGHALTONCOCRVOSKVIBOLTBDPTLYELIBOPULMBFRG (+300%, -100%)
Pharmaceutical Preparations; dot size is quarterly revenue; dashed lines are the industry's medians.

Interactive views

The same charts as the app — open one to draw it.

💵Where each $1 goesinteractive

Loading the interactive chart…

🌏Named in Asian annual reportsinteractive

Loading the interactive chart…

🔄Rotation against the market and its industry (RRG)interactive

Loading the interactive chart…

🔍Earnings qualityinteractive

Loading the interactive chart…

⚖️Fair value by methodinteractive

Loading the interactive chart…

🔭Outlook & guidanceinteractive

Loading the interactive chart…

📈Investments: gains and what it boughtinteractive

Loading the interactive chart…

🏭Its industry’s money flow (input-output)interactive

Loading the interactive chart…

About BullFrog AI Holdings

BullFrog AI Holdings, Inc. was incorporated in the State of Nevada in February 2020. BullFrog AI Holdings, Inc. is the parent company of BullFrog AI, Inc. and BullFrog AI Management, LLC, which were incorporated in Delaware and Maryland, in 2017 and 2021, respectively. All our operations are currently conducted through BullFrog AI Holdings, Inc. The Company’s principal business address is 325 Ellington Blvd, Unit 317, Gaithersburg, MD 20878. Our website address is www.bullfrogai.com . The references to our website in this Annual Report on Form 10-K (the “Form 10-K”) are inactive textual references only. The information on our website is not incorporated into this Form 10-K.

In its own words, from its 10-K, filed Mar 19, 2026.

BullFrog AI Holdings against its Pharmaceutical Preparations peers

The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +548% against the peers' median +10%. Operating margin: -658.8% against the peers' median 20.4%.

CompanyQuarterRevenueY/YOp. margin
BFRG BullFrog AI HoldingsQ2 2026$215K+548%-658.8%
JNJ Johnson & JohnsonQ3 2026$25.4B+6%0.1%
LLY ELI LillyQ3 2026$24.4B+39%34.5%
MRK MerckQ3 2026$18.1B+5%30.7%
ABBV AbbVieQ3 2026$17.4B+10%36.0%
PFE PfizerQ3 2026$16.6B-0.4%20.4%
BMY Bristol Myers SquibbQ3 2026$13.1B+7%19.4%
ABT Abbott LaboratoriesQ3 2026$13.0B+14%10.4%
REGN Regeneron PharmaceuticalsQ3 2026$5.1B+36%40.0%

Source: BullFrog AI Holdings 10-Q on SEC EDGAR · CIK 1829247 · Pharmaceutical Preparations

13F: who owns BFRG and who is buying

Largest holders of BFRG (13F)Largest holders of BFRG (13F)Citadel Advisors LLC$257KJ. Safra Sarasin Holding AG$191KVanguard Group$139KVanguard Fiduciary Trust$76KGeode Capital Management, LLC$74KVanguard Capital Management LLC$65KJane Street Group, LLC$47KRaymond James Financial$32KFortem Financial Group, LLC$30KACT Advisors, LLC.$22K
Funds' net buying of BFRG by quarter (13F)Funds' net buying of BFRG by quarter (13F)−$65K2024-09−$2K2024-12$163K2025-03−$130K2025-06−$15K2025-09$135K2025-12$145K2026-03$360K2026-06
Value of shares 13F filers added minus the value they sold, each quarter (quarters with most filings in).

More on BFRG

History

Every quarter: Q2 2026 results · Q3 2025 results · Q2 2025 results

Compare BFRG with

中文版:BullFrog AI Holdings(BFRG)财报

Español · Français